Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Novo moves into amyloidosis not long after Intellia made a splash here.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.